Bayer wins Roundup lawsuit, boosting shares by 11%

Bayer's stock surged after a U.S. appeals court ruled in favor of the company in a lawsuit claiming its Roundup weed killer caused cancer.

Ruxandra Iordache reports for CNBC.

In short:

• The 3rd U.S. Circuit Court of Appeals ruled that federal law prevents Pennsylvania from requiring a cancer warning on Roundup.
• The lawsuit involved a landscaper who claimed Roundup exposure caused his non-Hodgkin’s lymphoma.
• Bayer's victory may influence other ongoing lawsuits, potentially leading to a U.S. Supreme Court review.

Why this matters:

Bayer's legal battles over Roundup are far from over, with thousands of cases still pending. The outcome of these cases could impact regulations and future litigation involving herbicides.

Related EHN coverage:

• Monsanto Roundup trial win overturned by Oregon court
• Op-ed: If Bayer really wanted to stand with farmers, it would stop selling them toxics
• Organic diets reduce glyphosate exposure for pregnant people: Study